ACET Adicet Bio, Inc. - Common Stock
NASDAQ · Biotechnology · Lihat di SEC EDGAR ↗ tutup Okt 2, 2026 10-K/10-Q Agu 5, 2026
$6,50
· % dari rentang 52 mgg
· di atas terendah
· ke tinggi
$0,46rendah 52m
$9,97tinggi 52m
Kapitalisasi Pasar (MRQ)
$61M
P/E
-0.5
EPS
$-16.95
lencana Anda
Rentang 52M
$0–$10
Peringkat Analis
BUY
Target Harga
$35
P/E
-0.5
ROE
·
Margin Laba Bersih
·
Strip lencana Anda kosong — sematkan metrik di mana saja di halaman ini.
ACET Cuplikan Saham Harga, kapitalisasi pasar, P/E, EPS, ROE, utang/ekuitas, kisaran 52 minggu
Harga
$6.50
Kapitalisasi Pasar (MRQ)
$61M
P/E
-0.5
EPS
$-16.95
Rentang 52M
$0–$10
ACET Grafik Harga Saham OHLCV harian dengan indikator teknis — geser, perbesar, dan sesuaikan tampilan Anda
rentang
batang
Granularitas batang menyesuaikan dengan periode yang dipilih — arahkan kursor ke bagan untuk melihat buka/tinggi/rendah/tutup untuk sebuah batang.
Pemecahan saham
| Tanggal ex-dividen | Pemecahan | Tipe |
|---|---|---|
| 30 Des. 2025 | 1-for-16 | Terbalik |
| 16 Sep. 2020 | 1-for-7 | Terbalik |
Kinerja 10 Tahun Tren Pendapatan, laba bersih, margin, dan EPS
EPS$-16.952021-12-31 → 2025-12-31
Arus Kas Bebas·2018-12-31 → 2024-12-31
Valuasi & Rasio
Valuasi Rasio P/E, P/S, P/B, EV/EBITDA — apakah sahamnya mahal atau murah?
| Metrik | Tren 5 Tahun | ACET | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| P/E | -0.5rata-rata 5T ≈-3.0 | ≈-3.0 | · | · | |
| P/B (MRQ) | 0.5rata-rata 5T ≈1.1 | ≈1.1 | 1.2 | Kurang nilai | |
| Harga / FCF (TTM) | -0.7rata-rata 5T ≈-4.6 | ≈-4.6 | · | · | |
| Harga / Arus Kas (TTM) | -0.7rata-rata 5T ≈-5.8 | ≈-5.8 | · | · | |
| Price / Tangible Book (Harga / Nilai Buku Berwujud) | 0.5rata-rata 5T ≈1.0 | ≈1.0 | · | · |
Median rekan dihitung berdasarkan basis standar per metrik dan mungkin tidak selalu cocok dengan basis TTM/MRQ yang ditampilkan untuk saham ini.
Profitabilitas Margin kotor, operasional, dan bersih; ROE, ROA, ROIC
Belum ada data untuk grup rasio ini
Data fundamental belum cukup untuk menghitung grup rasio ini.
Kesehatan Keuangan Utang, likuiditas, solvabilitas — kekuatan neraca
| Metrik | Tren 5 Tahun | ACET | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| Rasio Lancar (MRQ) | 6.7rata-rata 5T ≈12.1 | ≈12.1 | 3.5 | Likuiditas kuat |
Pertumbuhan Pertumbuhan Pendapatan, EPS, dan Laba Bersih: YoY, CAGR 3T, CAGR 5T
Belum ada data untuk grup rasio ini
Data fundamental belum cukup untuk menghitung grup rasio ini.
Efisiensi Modal Perputaran aset, perputaran persediaan, perputaran piutang
Belum ada data untuk grup rasio ini
Data fundamental belum cukup untuk menghitung grup rasio ini.
nilai · ≈ rata-rata 5T · median industri · penilaian relatif terhadap median
Riwayat Pendapatan EPS aktual vs perkiraan, kejutan %, tingkat keberhasilan, tanggal pendapatan berikutnya
Kejutan Rata-rata
7.1%
Laporan Berikutnya
Nov 03, 2026
| Periode | Laporan | EPS Aktual | EPS Estimasi | Kejutan |
|---|---|---|---|---|
| 30 Juni 2026 | Agu 6, 2026 | $-1.99 | $-2.07 | 4.0% |
| 31 Maret 2026 | $-1.88 | $-3.17 | 40.7% | |
| 31 Des. 2025 | $-2.94 | $-2.86 | -2.9% | |
| 30 Sep. 2025 | $-4.64 | $-4.73 | 1.9% | |
| 30 Juni 2025 | $-5.44 | $-4.97 | -9.5% | |
| 31 Maret 2025 | $-4.96 | $-5.41 | 8.4% |
Fundamental Lengkap Semua metrik per tahun — laporan laba rugi, neraca, arus kas
Laporan Laba Rugi
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $99M | $99M | $106M | $71M | $49M | $34M | $24M | $15M | $17M | |
| SG&A Expense | $23M | $28M | $27M | $26M | $22M | $23M | $9M | $8M | $2M | |
| Operating Expenses | $122M | $128M | $152M | $98M | $71M | $57M | $32M | $23M | $19M | |
| Operating Income | $-122M | $-128M | $-152M | $-73M | $-61M | $-39M | $-31M | $-15M | $-19M | |
| Interest Expense | $36.0K | $4.0K | $25.0K | $80.0K | $176.0K | $134.0K | · | · | · | |
| Interest Income | $6M | $11M | $10M | · | · | · | · | · | · | |
| Other Non-op | $-430.0K | $-217.0K | $-573.0K | $-919.0K | $-606.0K | $-953.0K | $2M | $5M | $-15M | |
| Pretax Income | $-117M | $-117M | $-143M | $-70M | $-62M | $-39M | $-28M | $-10M | $-34M | |
| Income Tax | $0 | $0 | $0 | $0 | $-125.0K | $-3M | $19.0K | $-589.0K | $0 | |
| Net Income | $-117M | $-117M | $-143M | $-70M | $-62M | $-37M | $-28M | $-9M | $-34M | |
| EPS (Basic) | $-16.95 | $-21.33 | $-3.31 | $-1.70 | $-2.00 | · | · | · | · | |
| EPS (Diluted) | $-16.95 | $-21.33 | $-3.31 | $-1.70 | $-2.00 | · | · | · | · | |
| Shares (Basic) | 6,891,336 | 5,491,652 | 43,042,405 | 41,080,286 | 30,952,152 | 7,319,977 | 2,148,317 | 2,049,680 | · | |
| Shares (Diluted) | 6,891,336 | 5,491,652 | 43,042,405 | 41,080,286 | 30,952,152 | · | · | · | · | |
| EBITDA | · | $-128M | $-152M | $-73M | $-61M | · | $-85M | $-40M | · |
Neraca
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $39M | $56M | $160M | $258M | $278M | $84M | $11M | $9M | $53M | |
| Short-term Investments | · | · | $0 | · | · | · | · | · | $0 | |
| Prepaid Expense | $2M | $4M | $3M | $3M | $5M | $6M | $2M | $1M | $792.0K | |
| Other Current Assets | $314.0K | $737.0K | $457.0K | $336.0K | $2.0K | $229.0K | $179.0K | $15.0K | $84.0K | |
| Current Assets | $161M | $180M | $162M | $261M | $282M | $100M | $64M | $110M | $55M | |
| PP&E (Net) | $17M | $23M | $27M | $29M | $15M | $3M | $2M | $321.0K | $39.0K | |
| PP&E (Gross) | $44M | $44M | $42M | $37M | $21M | $8M | $6M | $406.0K | $44.0K | |
| Accum. Depreciation | $27M | $21M | $15M | $9M | $6M | $5M | $4M | $85.0K | $5.0K | |
| Goodwill | · | · | $0 | $19M | $19M | $20M | · | · | · | |
| Intangibles | · | · | · | · | $0 | · | · | · | · | |
| Other Non-current Assets | $76.0K | $428.0K | $822.0K | $1M | $2M | $2M | $410.0K | · | · | |
| Total Assets | $192M | $220M | $207M | $331M | $339M | $154M | $82M | $110M | $55M | |
| Accounts Payable | $5M | $5M | $3M | $4M | $3M | $2M | $1M | $3M | $2M | |
| Accrued Liabilities | · | · | · | · | · | · | $5M | $3M | $4M | |
| Current Liabilities | $22M | $19M | $19M | $20M | $16M | $22M | $15M | $6M | $6M | |
| Capital Leases | $11M | $14M | $18M | $19M | $19M | $20M | · | · | · | |
| Deferred Tax | · | · | · | · | · | $125.0K | · | · | · | |
| Other Non-current Liabilities | $62.0K | $116.0K | $130.0K | $114.0K | $115.0K | · | $15.0K | $19.0K | · | |
| Total Liabilities | $33M | $34M | $37M | $38M | $36M | $44M | $28M | $6M | $6M | |
| Common Stock | $10.0K | $5.0K | $4.0K | $4.0K | $4.0K | $2.0K | $4.0K | $3.0K | $1.0K | |
| Paid-in Capital | · | · | · | · | · | · | · | $176M | $2M | |
| Retained Earnings | $-615M | $-498M | $-381M | $-238M | $-168M | $-106M | $-70M | $-71M | $-34M | |
| AOCI | $102.0K | $16.0K | $0 | $0 | $0 | $24.0K | $23.0K | $-41.0K | · | |
| Stockholders' Equity | $159M | $187M | $170M | $292M | $303M | $110M | $-60M | $-34M | $-27M | |
| Liabilities + Equity | $192M | $220M | $207M | $331M | $339M | $154M | $82M | $110M | $55M | |
| Shares Outstanding | 9,586,770 | 5,160,545 | 43,270,386 | 42,954,820 | 39,736,914 | 39,736,914 | 2,155,578 | 28,055,344 | 5,659,089 |
Arus Kas
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $6M | $6M | $6M | $3M | $2M | $1M | $1M | $1M | $5.0K | |
| Stock-based Comp | $14M | $22M | $20M | $17M | $13M | $5M | $1M | $2M | $470.0K | |
| Deferred Tax | $0 | $0 | $0 | $0 | $-125.0K | $-242.0K | · | · | · | |
| Operating Cash Flow | $-95M | $-92M | $-94M | $-45M | $-51M | $-42M | $-28M | $-18M | $-11M | |
| CapEx | $2M | $1M | $4M | $17M | $13M | $990.0K | $1M | $876.0K | $44.0K | |
| Investing Cash Flow | $2M | $-119M | $-4M | $-17M | $-3M | $115M | $-48M | $-16M | $-44.0K | |
| Stock Issued | $0 | $19M | $0 | $43M | $238M | · | · | · | · | |
| Net Stock Activity | · | $19M | $0 | $0 | $238M | · | · | · | · | |
| Financing Cash Flow | $75M | $111M | $236.0K | $42M | $243M | $303.0K | $77M | $11M | $64M | |
| Net Change in Cash | $-18M | $-100M | $-98M | $-20M | $189M | $74M | $1M | $-23M | $53M | |
| Free Cash Flow | · | $-93M | $-98M | $-62M | $-64M | · | $-74M | $-36M | · | |
| Levered FCF | · | $-94M | $-98M | $-62M | $-64M | · | · | · | · |
Profitabilitas
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROA | · | -54.8% | -53.0% | -20.8% | -25.2% | · | -81.2% | -45.6% | · | |
| ROE | · | -58.8% | -78.2% | -22.9% | -23.8% | · | -600.2% | -35.2% | · | |
| ROIC | · | -68.4% | -89.3% | -24.8% | -20.2% | · | -104.7% | -38.1% | · |
Likuiditas & Solvabilitas
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | · | 9.3 | 8.4 | 13.2 | 17.3 | · | 7.6 | 19.2 | · | |
| Quick Ratio | · | 2.9 | 8.3 | 13.1 | 17.0 | · | 2.8 | 1.2 | · | |
| Interest Coverage | · | -31903.8 | -6081.5 | -906.9 | -349.1 | · | · | · | · |
Per Saham
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | · | $2.26 | $3.93 | $7.36 | $7.63 | · | $2.24 | $3.71 | · | |
| Cash Flow / Share | · | $-1.05 | $-2.18 | $-1.09 | · | · | · | · | · | |
| Cash / Share | · | $0.68 | $3.69 | $6.48 | $6.98 | · | $0.93 | $0.25 | · | |
| Dividend / Share | · | · | · | · | · | $0.00 | $0.00 | $0.00 | · | |
| Dividend Paid / Share | · | · | · | · | · | · | $0.00 | $0.00 | · | |
| EPS (TTM) | $-16.95 | $-21.33 | $-3.31 | $-1.70 | $-2.00 | · | · | · | · |
Valuasi (TTM)
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-117M | $-117M | $-143M | $-70M | $-62M | $-37M | $-28M | $-9M | $-34M | |
| Market Cap | · | $79M | $82M | $355M | $695M | · | $380M | $1.69B | · | |
| P/E | -0.5 | -0.0 | -0.6 | -5.3 | -8.7 | · | · | · | · | |
| P/B | · | 0.4 | 0.5 | 1.2 | 2.3 | · | 4.7 | 16.2 | · | |
| P / Tangible Book | 0.5 | 0.4 | 0.5 | 1.3 | 2.5 | 3.1 | · | · | · | |
| P / Cash Flow | · | -0.9 | -0.9 | -7.9 | -13.6 | · | -5.2 | -47.6 | · | |
| P / FCF | · | -0.8 | -0.8 | -5.8 | -10.8 | · | -5.1 | -47.2 | · | |
| Earnings Yield | -201.3% | -2217.3% | -175.1% | -19.0% | -11.4% | · | · | · | · |
Laporan Laba Rugi
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $18M | $17M | $25M | $23M | $28M | $23M | $23M | $26M | $26M | $24M | $25M | $26M | $28M | $27M | $25M | $17M | |
| SG&A Expense | $4M | $4M | $7M | $5M | $4M | $7M | $7M | $7M | $7M | $7M | $7M | $7M | $7M | $7M | $7M | $6M | |
| Operating Expenses | $22M | $22M | $32M | $28M | $32M | $30M | $31M | $33M | $33M | $31M | $32M | $52M | $35M | $33M | $32M | $23M | |
| Operating Income | $-22M | $-22M | $-32M | $-28M | $-32M | $-30M | $-31M | $-33M | $-33M | $-31M | $-32M | $-52M | $-35M | $-33M | $-32M | $-23M | |
| Interest Expense | $22.0K | $23.0K | $24.0K | $12.0K | $0 | $0 | $1.0K | $1.0K | $0 | $2.0K | $1.0K | $1.0K | $4.0K | $19.0K | $26.0K | $18.0K | |
| Interest Income | $1M | $1M | $2M | $1M | $1M | $2M | $2M | $3M | $3M | $3M | · | · | · | · | · | · | |
| Other Non-op | $-60.0K | $7.0K | $-131.0K | $-64.0K | $-223.0K | $-12.0K | $-51.0K | $-54.0K | $-51.0K | $-61.0K | $-101.0K | $-142.0K | $-124.0K | $-206.0K | $-462.0K | $-217.0K | |
| Pretax Income | $-21M | $-20M | $-31M | $-27M | $-31M | $-28M | $-29M | $-30M | $-30M | $-28M | $-29M | $-50M | $-32M | $-31M | $-30M | $-22M | |
| Income Tax | $143.0K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | · | $0 | $0 | $0 | |
| Net Income | $-21M | $-20M | $-31M | $-27M | $-31M | $-28M | $-29M | $-30M | $-30M | $-28M | $-29M | $-50M | $-32M | $-31M | $-30M | $-22M | |
| EPS (Basic) | $-1.99 | $-1.88 | $-16.01 | $-0.29 | $-5.48 | $-4.96 | $-20.31 | $-0.34 | $-0.33 | $-0.35 | $-0.68 | $-1.16 | $-0.75 | $-0.72 | $-0.73 | $-0.53 | |
| EPS (Diluted) | $-1.99 | $-1.88 | $-16.01 | $-0.29 | $-5.48 | $-4.96 | $-20.31 | $-0.34 | $-0.33 | $-0.35 | $-0.68 | $-1.16 | $-0.75 | $-0.72 | $-0.71 | $-0.53 | |
| Shares (Basic) | 10,745,553 | 10,744,621 | · | 91,086,464 | 5,692,816 | 5,691,965 | · | 90,846,293 | 90,632,045 | 79,071,652 | · | 42,980,641 | 42,957,035 | 42,955,688 | · | 41,642,815 | |
| Shares (Diluted) | 10,745,553 | 10,744,621 | · | 91,086,464 | 5,692,816 | 5,691,965 | · | 90,846,293 | 90,632,045 | 79,071,652 | · | 42,980,641 | 42,957,035 | 42,955,688 | · | 41,642,815 | |
| EBITDA | $-22M | $-22M | · | $-28M | $-32M | $-30M | · | $-33M | $-33M | $-31M | · | $-52M | $-35M | $-33M | · | $-23M |
Neraca
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $33M | $36M | $39M | $29M | $35M | $28M | $56M | $105M | $224M | $248M | $160M | $183M | $205M | $232M | $258M | $283M | |
| Short-term Investments | · | · | · | · | · | · | · | $97M | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $3M | $2M | $2M | $3M | $3M | $3M | $4M | $4M | $4M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | |
| Other Current Assets | $441.0K | $348.0K | $320.0K | $619.0K | $690.0K | $478.0K | $737.0K | $543.0K | $409.0K | $613.0K | $457.0K | $378.0K | $489.0K | $511.0K | $336.0K | $380.0K | |
| Current Assets | $121M | $140M | $161M | $106M | $128M | $154M | $180M | $206M | $228M | $250M | $162M | $186M | $209M | $235M | $261M | $286M | |
| PP&E (Net) | $14M | $15M | $17M | $18M | $20M | $21M | $23M | $24M | $24M | $25M | $27M | $28M | $30M | $30M | $29M | $27M | |
| PP&E (Gross) | $44M | $44M | $44M | $44M | $44M | $44M | $44M | $44M | $42M | $42M | $42M | $41M | $41M | $40M | $37M | $35M | |
| Accum. Depreciation | $30M | $29M | $27M | $26M | $24M | $23M | $21M | $20M | $18M | $16M | $15M | $13M | $12M | $10M | $9M | $8M | |
| Goodwill | · | · | · | · | · | · | · | · | · | · | · | $0 | $19M | $19M | $19M | $19M | |
| Other Non-current Assets | $80.0K | $78.0K | $76.0K | $110.0K | $225.0K | $314.0K | $428.0K | $508.0K | $593.0K | $691.0K | $822.0K | $916.0K | $1M | $1M | $1M | $1M | |
| Total Assets | $148M | $169M | $192M | $140M | $163M | $191M | $220M | $246M | $269M | $293M | $207M | $233M | $278M | $305M | $331M | $354M | |
| Accounts Payable | $4M | $3M | $5M | $4M | $3M | $4M | $5M | $2M | $2M | $3M | $3M | $4M | $3M | $3M | $4M | $5M | |
| Current Liabilities | $18M | $18M | $22M | $19M | $17M | $16M | $19M | $19M | $18M | $17M | $19M | $20M | $19M | $18M | $20M | $17M | |
| Capital Leases | $9M | $10M | $11M | $12M | $12M | $13M | $14M | $15M | $16M | $17M | $18M | $19M | $20M | $21M | $19M | $19M | |
| Other Non-current Liabilities | $0 | $0 | $62.0K | $125.0K | $116.0K | $116.0K | $116.0K | $116.0K | $116.0K | $116.0K | $130.0K | $143.0K | $130.0K | $116.0K | $114.0K | $116.0K | |
| Total Liabilities | $28M | $29M | $33M | $31M | $30M | $30M | $34M | $34M | $34M | $34M | $37M | $39M | $39M | $39M | $38M | $37M | |
| Common Stock | $1.0K | $1.0K | $10.0K | $8.0K | $8.0K | $8.0K | $5.0K | $8.0K | $8.0K | $8.0K | $4.0K | $4.0K | $4.0K | $4.0K | $4.0K | $4.0K | |
| Retained Earnings | $-656M | $-635M | $-615M | $-584M | $-557M | $-526M | $-498M | $-469M | $-439M | $-409M | $-381M | $-351M | $-301M | $-269M | $-238M | $-208M | |
| AOCI | $-105.0K | $-37.0K | $102.0K | $56.0K | $-41.0K | $-9.0K | $16.0K | $121.0K | · | · | $0 | · | $0 | $0 | · | $0 | |
| Stockholders' Equity | $120M | $140M | $159M | $109M | $133M | $161M | $187M | $212M | $235M | $259M | $170M | $195M | $239M | $266M | $292M | $318M | |
| Liabilities + Equity | $148M | $169M | $192M | $140M | $163M | $191M | $220M | $246M | $269M | $293M | $207M | $233M | $278M | $305M | $331M | $354M | |
| Shares Outstanding | 9,361,371 | 9,597,693 | 9,586,770 | 83,253,779 | 83,252,520 | 82,709,625 | 5,160,545 | 82,400,960 | 82,400,960 | 82,169,503 | 43,270,386 | 43,107,921 | 43,066,158 | 42,957,431 | 42,954,820 | 42,787,657 |
Arus Kas
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $1M | $800.0K | |
| Stock-based Comp | $1M | $1M | $6M | $2M | $3M | $3M | $4M | $7M | $6M | $6M | $5M | $6M | $5M | $5M | $4M | $4M | |
| Operating Cash Flow | $-20M | $-21M | $-21M | $-22M | $-27M | $-25M | $-24M | $-22M | $-23M | $-23M | $-23M | $-21M | $-25M | $-24M | $-19M | $-15M | |
| CapEx | $202.0K | $37.0K | $-10.0K | $209.0K | $47.0K | $1M | $176.0K | $401.0K | $302.0K | $239.0K | $136.0K | $906.0K | $2M | $2M | $6M | $5M | |
| Investing Cash Flow | $17M | $19M | $-45M | $17M | $33M | $-3M | $-22M | $-97M | $-302.0K | $-239.0K | $-136.0K | $-906.0K | $-2M | $-2M | $-6M | $-5M | |
| Stock Issued | · | · | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $19M | $0 | $0 | $0 | $0 | $0 | $43M | |
| Net Stock Activity | · | · | · | · | · | $0 | · | · | · | $19M | · | · | · | · | · | · | |
| Financing Cash Flow | $58.0K | $-65.0K | $75M | $-150.0K | $267.0K | $-104.0K | $137.0K | $0 | $204.0K | $111M | $76.0K | $-59.0K | $226.0K | $-7.0K | $304.0K | $42M | |
| Net Change in Cash | $-3M | $-3M | $10M | $-6M | $7M | $-28M | $-46M | $-119M | $-24M | $88M | $-24M | $-22M | $-26M | $-26M | $-25M | $22M | |
| Free Cash Flow | · | $-22M | · | · | · | $-27M | · | · | · | $-23M | · | · | · | $-26M | · | · | |
| Levered FCF | · | $-22M | · | · | · | $-27M | · | · | · | $-23M | · | · | · | $-26M | · | · |
Profitabilitas
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROA | -13.7% | -11.2% | · | -13.9% | -14.5% | -11.7% | · | -12.7% | -10.9% | -9.4% | · | -17.0% | -10.7% | -9.6% | · | -7.2% | |
| ROE | -16.9% | -13.4% | · | -16.8% | -16.9% | -13.4% | · | -15.0% | -12.6% | -10.7% | · | -19.5% | -12.2% | -10.7% | · | -8.2% | |
| ROIC | -18.7% | -15.4% | · | -25.6% | -24.3% | -18.5% | · | -15.7% | · | -11.9% | · | -26.9% | -14.6% | -12.5% | · | -7.2% |
Likuiditas & Solvabilitas
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.7 | 7.7 | · | 5.6 | 7.5 | 9.3 | · | 10.6 | 12.8 | 14.3 | · | 9.4 | 11.1 | 13.0 | · | 16.6 | |
| Quick Ratio | 1.8 | 2.0 | · | 1.5 | 2.0 | 1.7 | · | 10.4 | 12.5 | 14.2 | · | 9.3 | 10.9 | 12.8 | · | 16.4 | |
| Interest Coverage | -1013.7 | -937.8 | · | -2329.3 | · | · | · | -33153.0 | · | -15435.5 | · | -52262.0 | -8722.5 | -1753.8 | · | -1276.9 |
Per Saham
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $12.83 | $14.59 | · | $1.31 | $1.60 | $1.95 | · | $2.57 | $2.85 | $3.15 | · | $4.52 | $5.55 | $6.20 | · | $7.42 | |
| Cash Flow / Share | · | $-2.00 | · | · | · | $-0.28 | · | · | · | $-0.29 | · | · | · | $-0.56 | · | · | |
| Cash / Share | $3.54 | $3.78 | · | $0.35 | $0.42 | $0.34 | · | $1.28 | $2.72 | $3.01 | · | $4.25 | $4.77 | $5.39 | · | $6.61 | |
| EPS (TTM) | $-20.17 | $-23.66 | · | $-31.04 | $-31.09 | $-25.94 | · | $-1.70 | $-2.52 | $-2.94 | · | $-3.34 | $-2.71 | $-2.52 | · | $-1.39 |
Valuasi (TTM)
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-99M | $-109M | · | $-115M | $-119M | $-117M | · | $-118M | $-137M | $-140M | · | $-143M | $-115M | $-105M | · | $-56M | |
| Market Cap | $81M | $65M | · | $67M | $51M | $62M | · | $119M | $100M | $193M | · | $59M | $105M | $247M | · | $608M | |
| P/E | -0.4 | -0.3 | · | -0.0 | -0.0 | -0.0 | · | -0.8 | -0.5 | -0.8 | · | -0.4 | -0.9 | -2.3 | · | -10.2 | |
| P/B | 0.7 | 0.5 | · | 0.6 | 0.4 | 0.4 | · | 0.6 | 0.4 | 0.7 | · | 0.3 | 0.4 | 0.9 | · | 1.9 | |
| P / Tangible Book | 0.7 | 0.5 | · | 0.6 | 0.4 | 0.4 | · | 0.6 | 0.4 | 0.7 | · | 0.3 | 0.5 | 1.0 | · | 2.0 | |
| P / Cash Flow | · | -3.0 | · | · | · | -2.5 | · | · | · | -8.5 | · | · | · | -10.3 | · | · | |
| Earnings Yield | -233.4% | -347.4% | · | -3832.1% | -5096.7% | -3435.8% | · | -118.1% | -208.3% | -125.1% | · | -243.8% | -111.5% | -43.8% | · | -9.8% |
Periode terbaru di sebelah kiri · nilai null ditampilkan sebagai ·
Laporan Keuangan Laporan laba rugi, neraca, arus kas — tahunan, 5 tahun terakhir
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Laba Bersih | $-117M | $-117M | $-143M | $-70M | $-62M |
| EPS Dilusian | $-16.95 | $-21.33 | $-3.31 | $-1.70 | $-2.00 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Rasio Lancar | · | 9.3 | 8.4 | 13.2 | 17.3 |
| Rasio Cepat | · | 2.9 | 8.3 | 13.1 | 17.0 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Arus Kas Bebas | · | $-93M | $-98M | $-62M | $-64M |
Pemilik institusional (13F) 62 pengaju · $57.4M total · Per tanggal 30 Juni 2026
Institusi yang melaporkan kepemilikan saham ini dalam SEC Form 13F triwulanan mereka. Hanya posisi panjang; satu pengaju dapat muncul dua kali untuk leg opsi terpisah. Kaki put/call offset yang besar biasanya mencerminkan pembuatan pasar atau inventaris yang dilindungi, bukan keyakinan arah.
Pemegang
62
Nilai yang dipegang
$57.4M
Posisi baru
17
Posisi yang keluar
6
Aktivitas institusional — Q2 2026 vs kuartal sebelumnya
| Posisi baru | Posisi yang keluar | Meningkat | Menurun | Perubahan bersih saham |
|---|---|---|---|---|
| 17 (+4 vs Kuartal sebelumnya) | 6 (-4 vs Kuartal sebelumnya) | 18 (+6 vs Kuartal sebelumnya) | 9 (+1 vs Kuartal sebelumnya) | -300K |
Dibandingkan dengan Q1 2026. Pengajuan Formulir 13F SEC jatuh tempo dalam waktu 45 hari setelah akhir kuartal ditambah kelonggaran singkat untuk pengaju terlambat — kuartal yang masih dalam jangka waktu tersebut dilewati demi pasangan terakhir yang dilaporkan sepenuhnya.
| Institusi | Nilai | Saham | % dari 13F yang dilacak | Tipe |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | $8.057.871 | 932.624 | 14,03% | Saham |
| ORBIMED ADVISORS LLC | $7.298.960 | 844.787 | 12,71% | Saham |
| FRANKLIN RESOURCES INC | $5.413.573 | 626.571 | 9,43% | Saham |
| CITADEL ADVISORS LLC | $3.738.856 | 432.738 | 6,51% | Saham |
| VANGUARD CAPITAL MANAGEMENT LLC | $2.965.490 | 343.228 | 5,17% | Saham |
| VANGUARD GROUP INC | $2.452.552 | 291.277 | 4,27% | Saham |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $2.370.600 | 274.375 | 4,13% | Saham |
| RENAISSANCE TECHNOLOGIES LLC | $2.297.765 | 265.945 | 4,00% | Saham |
| Stonepine Capital Management, LLC | $2.121.276 | 245.518 | 3,69% | Saham |
| Aquilo Capital Management, LLC | $1.854.426 | 2.456.194 | 3,23% | Saham |
| Alyeska Investment Group, L.P. | $1.760.823 | 203.799 | 3,07% | Saham |
| Schonfeld Strategic Advisors LLC | $1.689.238 | 195.514 | 2,94% | Saham |
| Carlyle Group Inc. | $1.592.308 | 184.295 | 2,77% | Saham |
| NEXTBio Capital Management LP | $1.363.625 | 157.827 | 2,38% | Saham |
| TWO SIGMA ADVISERS, LP | $937.449 | 111.336 | 1,63% | Saham |
| TWO SIGMA INVESTMENTS, LP | $836.689 | 96.839 | 1,46% | Saham |
| GEODE CAPITAL MANAGEMENT, LLC | $826.703 | 95.634 | 1,44% | Saham |
| DAFNA Capital Management LLC | $810.536 | 93.812 | 1,41% | Saham |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | $742.686 | 85.959 | 1,29% | Saham |
| MARSHALL WACE, LLP | $686.775 | 79.488 | 1,20% | Saham |
| Trexquant Investment LP | $673.937 | 78.002 | 1,17% | Saham |
| JANE STREET GROUP, LLC | $609.647 | 70.561 | 1,06% | Saham |
| Burkehill Global Management, LP | $540.000 | 62.500 | 0,94% | Saham |
| BlackRock, Inc. | $536.769 | 62.126 | 0,93% | Saham |
| REGENERON PHARMACEUTICALS, INC. | $522.819 | 60.511 | 0,91% | Saham |
| Rangeley Capital, LLC | $439.707 | 50.892 | 0,77% | Saham |
| VANGUARD FIDUCIARY TRUST CO | $437.789 | 50.670 | 0,76% | Saham |
| RBF Capital, LLC | $333.348 | 38.582 | 0,58% | Saham |
| STATE STREET CORP | $312.958 | 36.222 | 0,55% | Saham |
| Quadrature Capital Ltd | $312.708 | 36.193 | 0,54% | Saham |
| DIMENSIONAL FUND ADVISORS LP | $273.049 | 31.603 | 0,48% | Saham |
| UBS Group AG | $257.619 | 29.817 | 0,45% | Saham |
| Verdad Advisers, LP | $217.728 | 25.200 | 0,38% | Saham |
| XTX Topco Ltd | $209.814 | 24.284 | 0,37% | Saham |
| CITADEL ADVISORS LLC | $196.992 | 22.800 | 0,34% | Opsi jual |
| JOHNSON & JOHNSON | $196.811 | 22.779 | 0,34% | Saham |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $178.416 | 20.650 | 0,31% | Saham |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $169.344 | 19.600 | 0,29% | Opsi jual |
| PRELUDE CAPITAL MANAGEMENT, LLC | $160.272 | 18.550 | 0,28% | Saham |
| NORTHERN TRUST CORP | $159.287 | 18.436 | 0,28% | Saham |
| OCCUDO QUANTITATIVE STRATEGIES LP | $143.735 | 16.636 | 0,25% | Saham |
| Squarepoint Ops LLC | $131.795 | 15.254 | 0,23% | Saham |
| Vontobel Holding Ltd. | $119.025 | 13.776 | 0,21% | Saham |
| AXQ CAPITAL, LP | $94.962 | 10.991 | 0,17% | Saham |
| Jump Financial, LLC | $94.539 | 10.942 | 0,16% | Saham |
| CITADEL ADVISORS LLC | $92.534 | 10.710 | 0,16% | Opsi beli |
| Arax Advisory Partners | $51.840 | 6.000 | 0,09% | Saham |
| Vanguard Global Advisers, LLC | $45.109 | 5.221 | 0,08% | Saham |
| SIMPLEX TRADING, LLC | $41.592 | 4.814 | 0,07% | Saham |
| MORGAN STANLEY | $19.795 | 2.291 | 0,03% | Saham |
Aktivis & pemilik 5%+ 7 saham
Investor yang mengajukan Jadwal 13D SEC — kepemilikan manfaat di atas 5% dengan niat untuk memengaruhi penerbit (kepemilikan aktivis, kampanye dewan, M&A). Setiap baris menunjukkan status terbaru yang diketahui dari posisi pengaju tersebut.
| Pengaju | Diajukan | Kepemilikan | Status | Tujuan | Pengajuan |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC, ORBIMED CAPITAL GP VI LLC, ORBIMED CAPITAL GP V LLC, OrbiMed Genesis GP LLC, ORBIMED ADVISORS ISRAEL II LTD, ORBIMED ISRAEL GP II, L.P., ORBIMED ISRAEL GP LTD., ORBIMED ISRAEL BIOFUND GP LIMITED PARTNERSHIP ×10 pengajuan | 10 April 2026 | 8,80% | Amandemen | · | SEC |
| The Carlyle Group Inc., Carlyle Holdings I GP Inc., Carlyle Holdings I GP Sub L.L.C., Carlyle Holdings I L.P., CG Subsidiary Holdings L.L.C., TC Group, L.L.C., Carlyle Investment Management L.L.C., Carlyle Genesis UK LLC, Abingworth LLP, Abingworth Bioventures 8 LP ×2 pengajuan | 7 Feb. 2024 | · | Pengajuan awal | · | SEC |
| Abingworth LLP, Abingworth Bioventures 8, LP ×2 pengajuan | 16 Maret 2021 | · | Pengajuan awal | · | SEC |
| aMoon Growth Fund Limited Partnership (f/k/a aMoon 2 Fund Limited Partnership), aMoon Growth Fund G.P. Limited Partnership (f/k/a aMoon 2 Fund G.P. Limited Partnership), aMoon General Partner Ltd., Dr. Yair C. Schindel | 18 Feb. 2021 | · | Pengajuan awal | · | SEC |
| aMoon 2 Fund Limited Partnership, aMoon 2 Fund G.P. Limited Partnership, aMoon General Partner Ltd., Dr. Yair C. Schindel ×2 pengajuan | 3 Des. 2020 | · | Pengajuan awal | · | SEC |
| Adicet Bio, Inc. | 8 Mei 2020 | · | Pengajuan awal | M&A / penjualan | SEC |
| PureTech Health LLC, PureTech Health plc ×3 pengajuan | 5 Mei 2020 | · | Pengajuan awal | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Orang dalam perusahaan 28 orang dalam · 11 pejabat · 15 direktur
| Orang Dalam | Peran | Aktivitas terakhir | Saham dimiliki | Beli 12m | Jual 12m | Bersih 12m |
|---|---|---|---|---|---|---|
| Chen Schor | President & CEO | 19 Juni 2026 A | 6.820 | 0 | 0 | $0 |
| Brian Nicholas Harvey | Chief Financial Officer | 25 Maret 2026 A | 5.145 | 0 | 0 | $0 |
| Lloyd Klickstein | Chief Medical Officer | 5 Agu 2026 A | 108.566 | 0 | 0 | $0 |
| Blake Aftab | Chief Scientific Officer | 19 Juni 2026 A | 2.981 | 0 | 0 | $0 |
| Julia D. Maltzman | Chief Medical Officer | 25 Maret 2026 A | · | 0 | 0 | $0 |
| Don Healey | Chief Technology Officer | 25 Maret 2026 A | 3.452 | 0 | 0 | $0 |
| Francesco Galimi | SVP & Chief Medical Officer | 5 Juni 2024 A | 101.801 | 0 | 0 | $0 |
| Carrie Krehlik | Chief Human Resources Officer | 12 Feb. 2021 A | · | 0 | 0 | $0 |
| Joan Mannick | Chief Medical Officer | 6 Des. 2019 A | 1.404.585 | 0 | 0 | $0 |
| John J Mccabe | Vice President, Finance | 6 Des. 2019 A | 12.867 | 0 | 0 | $0 |
| Meredith Manning | Chief Commercial Officer | 27 Feb. 2019 A | · | 0 | 0 | $0 |
| Katie Peng | Direktur | 21 Juni 2026 A | 11.800 | 0 | 0 | $0 |
| Andrew Sinclair | Direktur | 21 Juni 2026 A | 17.700 | 0 | 0 | $0 |
| Michael Grissinger | Direktur | 21 Juni 2026 A | · | 0 | 0 | $0 |
| Jeffrey Chodakewitz | Direktur | 21 Juni 2026 A | 17.700 | 0 | 0 | $0 |
| Steve Dubin | Direktur | 21 Juni 2026 A | 22.700 | 0 | 0 | $0 |
| Aya Jakobovits | Direktur | 21 Agu 2024 A | 11.800 | 0 | 0 | $0 |
| Michael Kauffman | Direktur | 21 Agu 2024 A | 5.900 | 0 | 0 | $0 |
| GORDON CARL L | Direktur | 21 Agu 2024 A | 11.800 | 0 | 0 | $0 |
| Bastiano Sanna | Direktur | 14 Agu 2023 A | 5.900 | 0 | 0 | $0 |
| CHIMOVITS EREZ | Direktur | 12 Feb. 2021 A | 396.657 | 0 | 0 | $0 |
| David Adam Steinberg | Direktur | 3 Juni 2020 A | · | 0 | 0 | $0 |
| Paul R. Fonteyne | Direktur | 3 Juni 2020 A | · | 0 | 0 | $0 |
| Jonathan Silverstein | Direktur | 3 Juni 2020 A | 4.830.387 | 0 | 0 | $0 |
| PureTech Health LLC | Pemilik 10% | 18 Des. 2019 S | 2.119.696 | 0 | 0 | $0 |
| Stewart Abbot | · | 11 Juni 2021 A | · | 0 | 0 | $0 |
| Yair Chaim Schindel | · | 17 Sep. 2020 A | 1.104.460 | 0 | 0 | $0 |
| Lynne Marie Sullivan | · | 3 Juni 2020 A | · | 0 | 0 | $0 |
Orang dalam dari pengajuan SEC Form 3/4/5; bersih = hanya P/S pasar terbuka
Kepemilikan ETF Dimiliki oleh 4 ETF
Bobot mencerminkan kepemilikan ekuitas langsung (N-PORT) saja; dana berbasis leverage atau derivatif mungkin memiliki eksposur swap tambahan yang tidak ditampilkan.
ACET Konsensus Analis Opini analis bullish dan bearish, target harga 12 bulan, potensi kenaikan
peringkat · 12 analis
BELI
Target median
$24.00
+269,2%
5 41,7%
Beli Kuat
6 50,0%
Beli
1 8,3%
Tahan
0 0,0%
Jual
0 0,0%
Jual Kuat
Target Harga 12 Bulan
6 analis · 2026-09-30Target rata-rata $34.83 +435,9%
← Di bawah semua target
Harga saat ini $6.50
Rendah$18.00
Rata-rata$34.83
Tinggi$90.00
Perbandingan rekan (sub-industri GICS) Metrik utama vs rekan sektor
Dasar FY, harga per penutupan akhir tahun fiskal terakhir setiap perusahaan.
| Ticker | Kapitalisasi Pasar | P/E | Pendapatan YoY | Margin Bersih | ROE | Margin Kotor |
|---|---|---|---|---|---|---|
| ACET | · | -0.5 | · | · | · | · |
| APLM | · | -2.5 | · | -128.7% | -1305.4% | · |
| CNTB | $159M | -2.8 | -99.8% | -86687.5% | -97.9% | · |
| IBIO | $97M | -5.5 | -75.0% | -33044.0% | -65.7% | · |
| GOSS | $724M | -4.1 | -57.7% | -351.5% | 201.8% | · |
| INKT | · | -3.8 | 4.5% | -6931.8% | 63.4% | · |
| NMAD | · | · | · | · | · | · |
| KLRS | $193M | -3.0 | · | · | -65.8% | · |
| FRMM | · | · | · | -6881.3% | -368.1% | · |
| BOLD | $27M | -0.5 | · | · | -46.7% | · |
| CLNN | $64M | · | -41.5% | -13086.5% | 200.2% | · |
Metrik Saya Daftar pantauan pribadi Anda — baris yang dipilih dari Fundamental Lengkap
Pilih metrik yang penting bagi Anda — klik + di sebelah baris mana pun di Fundamental Lengkap di atas.
Pilihan Anda disimpan dan mengikuti Anda di semua ticker.
Sumber: SEC 10-Q diajukan Agu 5, 2026